In Vietnam, 65% of individuals diagnosed with hepatocellular carcinoma (HCC) are at the advanced stage, with a 5-year survival rate of less than 5%. While HCC surveillance in Vietnam relies on the use of ultrasound + AFP,  this method has limitations in detecting early-stage HCC.

As Lab Manager for MEDIC Center, the largest private lab group in South Vietnam, Dr Bao Toan Nguyen implemented PIVKA-II to improve the early detection of HCC, the most common type of cancer in Vietnam.

In this Q&A, Dr Nguyen shares his experience with serum biomarkers PIVKA-II and AFP for HCC early diagnosis and surveillance. He also shares several case studies that highlight the clinical value of this approach.

This video originally appeared on Clinicalvalue.com. The video with full transcript can also be seen here.